Frank Seebach - Concepedia

Author

Frank Seebach

Regeneron (United States)

Also Known As

F. Seebach, F.A. Seebach, FRANK SEEBACH, Frank A. Seebach, Frank Seebach

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Regeneron (United States)Moffitt Cancer Center Stanford University The University of Texas MD Anderson Cancer Center University Hospital Schleswig-Holstein

About

Frank Seebach is an author at Regeneron (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.4K
2	Health Sciences	4	4	937
3	Immunology	2	2	49
4	Cell Biology	1	1	22
5	Hepatology	1	1	56

Frank Seebach

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, New England Journal of Medicine	2018	1.3K
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko, The Lancet RadiologyMedicineBronchial NeoplasmImmune Checkpoint InhibitorFirst-line Treatment	2021	772
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma Neil D. Gross, David M. Miller, Nikhil I. Khushalani, New England Journal of Medicine	2022	288
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, Nature Medicine	2022	268
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial Alexander Stratigos, Aleksandar Sekulić, Ketty Peris, The Lancet Oncology MedicineHedgehog Inhibitor TherapyDermatologyCancer TreatmentOncology	2021	266
Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study Neil D. Gross, David M. Miller, Nikhil I. Khushalani, The Lancet Oncology Surgical OncologySurvival OutcomesNeoadjuvant CemiplimabMedicineSurgery	2023	90
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, Journal of Thoracic Oncology	2023	85
Endogenous Heparin-Like Substances Significantly Impair Coagulation in Patients Undergoing Orthotopic Liver Transplantation Stephan C. Kettner, C. Gonano, Frank Seebach, Anesthesia & Analgesia	1998	83
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial Mustafa Özgüroğlu, Ahmet Sezer, Mahmut Gümüş, The Lancet Oncology First-line Cemiplimab MonotherapyEmpower-lung 1MedicineCancer ManagementPd-l1 50	2023	82
Functional Activation of Heat Shock Factor and Hypoxia-Inducible Factor in the Kidney Oliver Eickelberg, Frank Seebach, Michael Riordan, Journal of the American Society of Nephrology	2002	68

Page 1